Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C53H84NO14P |
Molecular Weight | 990.2082 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1([H])/C(/[H])=C(\[H])/C(/[H])=C(\[H])/C(/[H])=C(\C)/[C@]([H])(C[C@]2([H])CC[C@@]([H])(C)[C@@](C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O[C@@]([H])(CC(=O)[C@]([H])(C)/C(/[H])=C(\C)/[C@]([H])([C@]([H])(C(=O)[C@]([H])(C)C1)OC)O)[C@]([H])(C)C[C@]4([H])CC[C@]([H])([C@@]([H])(C4)OC)OP(=O)(C)C)(O)O2)OC
InChI
InChIKey=BUROJSBIWGDYCN-GAUTUEMISA-N
InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
DescriptionCurator's Comment:: Description was created based on several sources, including
https://www.drugs.com/history/ridaforolimus.html
https://www.ncbi.nlm.nih.gov/pubmed/20945947
Curator's Comment:: Description was created based on several sources, including
https://www.drugs.com/history/ridaforolimus.html
https://www.ncbi.nlm.nih.gov/pubmed/20945947
Ridaforolimus (Deforolimus, MK-8669) is an investigational oral mTOR inhibitor in development for the treatment of metastatic soft-tissue or bone sarcomas. Ridaforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. Ridaforolimus (Deforolimus, MK-8669) is a selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. mTOR is a protein kinase that controls cell growth by regulating many cellular processes, including protein synthesis and autophagy. Compared with other mTOR inhibitors, ridaforolimus is not a prodrug and has shown in vivo stability. Both intravenous and oral formulations of the compound are being tested in clinical trials for the treatment of various solid tumors and hematologic malignancies. The initial indication is soft-tissue and bone sarcomas. Ridaforolimus was indicated to treat patients with metastatic soft tissue sarcoma or bone sarcoma whose disease has not progressed after at least 4 cycles of chemotherapy. In June 2012, Merck & Co., Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for ridaforolimus had not been approved. Currently Ridaforolimus is in phase III clinical trials for the treatment of Coronary artery restenosis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22037923
Curator's Comment:: Ridaforolimus can cross the blood-brain barrier in areas of tumor involvement, and may inhibit mTOR activity in advanced gliomas based on decreased pS6 levels.
Originator
Approval Year
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21482695
Treatment of HT-1080 cells with Deforolimus induces a dose-dependent inhibition of phosphorylation of both S6 and 4E-BP1, with IC50 of 0.2 nM and 5.6 nM, respectively, and leads to a decrease in cell size, an increase in the proportion of cells in the G1 phase of the cell cycle, and inhibition of glucose uptake. Deforolimus displays significant antiproliferative activity a broad panel of cell lines with EC50 of 0.2-2.3 nM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
207805
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
||
|
WHO-VATC |
QL01XE19
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
||
|
FDA ORPHAN DRUG |
207705
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
||
|
NCI_THESAURUS |
C2201
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
||
|
WHO-ATC |
L01XE19
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
572924-54-0
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
C49061
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
11520894
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
CHEMBL2103839
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
48Z35KB15K
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
4778
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
RIDAFOROLIMUS
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
DB06233
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
SUB32091
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
8822
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | |||
|
M9606
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY | Merck Index | ||
|
C515074
Created by
admin on Sat Jun 26 15:22:14 UTC 2021 , Edited by admin on Sat Jun 26 15:22:14 UTC 2021
|
PRIMARY |
ACTIVE MOIETY